Skip to content

Clinical trials

Phase 1 Urinary Bladder Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Urinary Bladder Neoplasms Phase: Phase 1 Country / region: United States Clear all

194 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20015
20021
20034
20046
20054
20066
20073
20081
20091
20105
20117
20125
20136
20144
201511
201612
20179
20188
201912
202014
20218
20229
202311
20247
202511
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed108
Terminated28
Recruiting23
Active, not recruiting20
Withdrawn7
Unknown status5
Not yet recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)17
Memorial Sloan Kettering Cancer Center7
M.D. Anderson Cancer Center6
Pfizer6
Eli Lilly and Company5
H. Lee Moffitt Cancer Center and Research Institute4
Jonsson Comprehensive Cancer Center4
MacroGenics4
University of California, Davis4
Celldex Therapeutics3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Urinary Bladder Neoplasms194
Carcinoma, Non-Small-Cell Lung73
Breast Neoplasms57
Ovarian Neoplasms54
Pancreatic Neoplasms47
Carcinoma, Renal Cell44
Colorectal Neoplasms44
Prostatic Neoplasms43
Stomach Neoplasms43
Lung Neoplasms41

Trials

Showing 1 to 25 of 194. Each trial links to its page on Pharma Observatory.

94 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.